Q Fever News and Research

RSS

Normoglycaemia key to improved neurological outcome after paediatric stroke

Achieving normal blood glucose concentrations may be important in preventing poor neurological outcomes in children following acute arterial ischemic stroke, a retrospective review indicates.

27 May 2016

Vision Express advises Britons to be 'sun safe' when choosing eyewear

Britons are putting their sight at risk – potentially exposing themselves to cataracts and macular degeneration – by choosing vanity over UV protection when buying sunglasses, new research from Vision Express has revealed.

From Vision Express 26 May 2016

Pre-treatment with antihistamines may suppress gastrointestinal symptoms of food allergy

Simultaneous pre-treatment with antihistamines that block both the H1 and H4 antihistamine receptors suppressed the gastrointestinal symptoms of food allergy in mice, according to researchers at National Jewish Health.

26 May 2016

Nutrition, safety tips for grilling season

Cooking meat, including beef, pork, fish, or poultry, with high-temperature methods such as pan frying or grilling directly over an open flame can increase exposure to chemicals that can cause changes in DNA that may increase the risk of cancer, according to the National Cancer Institute.

25 May 2016

New data-intensive supercomputer may help combat spread of Zika virus

More than 50 data scientists, engineers, and UT Austin students gathered on Sunday, May 15, 2016 to use Big Data to fight the spread of Zika for the "Austin Zika Hackathon" at the Cloudera offices downtown.

23 May 2016

Research provides pathway toward creation of first broad-spectrum antiviral drug

By studying the rare person -- about one in a million -- who can fight off viral infections more effectively than everyone else, investigators at the Icahn School of Medicine at Mount Sinai have developed a strategy to help the rest of us achieve this enhanced anti-viral state.

21 May 2016

NS5 viral protein could be promising vaccine target against Zika virus

A viral protein known as NS5 is a promising target for vaccines against Zika and related viruses, according to National Institutes of Health scientists and colleagues at Mount Sinai's Icahn School of Medicine.

20 May 2016

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.

19 May 2016

Tackling Zika: are insect repellents the answer? An interview with Bruno Jactel

The repellents that are used today are mostly based on what we call chemical pesticides. These products are used to repel mosquitoes as well as ticks. They are very broadly used, but there are different issues surrounding their use.

19 May 2016

Experimental hepatitis C drug slows down development of Zika in mice

Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy.

17 May 2016

WHO/PAHO statement on Zika virus and the 2016 Rio Olympic and Paralympic Games

The World Health Organization (WHO) and the Pan American Health Organization (PAHO) recognize that athletes and visitors are seeking more information on the risks of Zika and ways to prevent infection while attending the 2016 Rio Olympic and Paralympic Games (5 August to 18 September 2016).

16 May 2016

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States.

16 May 2016

Rotavirus vaccine program reduces hospitalization rates by more than 70% in Ontario

Hospitalization for rotavirus infections decreased by > 70% following the introduction of a vaccine program in Ontario, Canada, according to a study published May 11, 2016 in the open-access journal PLOS ONE by Sarah Wilson from Public Health Ontario and the Institute for Clinical Evaluative Sciences, Canada, and colleagues.

13 May 2016

Mosquito larvae carries Sindbis virus that can cause Ockelbo disease

After an outbreak of Ockelbo disease in northern Sweden in 2013, researchers at Umeå University were able to trace the virus to mosquitos in an area of Lövånger. In a new study, researchers have shown that mosquito larvae in the Västerbotten region also carry virus that can cause infectious disease. These include the Sindbis virus, which causes Ockelbo disease, which is associated with fever, rashes and prolonged joint pain.

13 May 2016

Researchers investigate effects of non-allergenic components of pollen on allergy sufferers

Up to now, research into pollen allergies has largely focused on allergens - those components of pollen that trigger hypersensitivity reactions. When it comes into contact with the nasal mucous membrane, however, pollen releases a host of other substances in addition to allergens.

13 May 2016

Drug-repositioning strategy could help combat Chikungunya virus

Since 2013, the mosquito-borne Chikungunya virus has spread rapidly through South America and the Caribbean, and is now threatening Southern Europe and the southern US.

13 May 2016

Yellow fever outbreak: Researchers emphasize need to prepare for global health emergency

Evidence is mounting that the current outbreak of yellow fever is becoming the latest global health emergency, say two Georgetown University professors, who call on the World Health Organization to convene an emergency committee under the International Health Regulations. In addition, with frequent emerging epidemics, they call for the creation of a "standing emergency committee" to be prepared for future health emergencies.

10 May 2016

Ebola vaccine shows promise in clinical trials

"The results for tolerability, safety, and the immune response to the vaccine candidate are very promising," explains Prof Marylyn Addo. The antibodies which developed against the virus were still detectable after six months. Addo is convinced, "With this, a single vaccine could provide lasting protection against Ebola." The infectious disease specialist, who works for the German Center for Infection Research at the University Medical Center Hamburg Eppendorf in Hamburg, led the trial in Hamburg.

4 May 2016

Study sheds light on several aspects of Ebola virus flare-ups in Liberia

Ebola virus samples taken from patients in Liberia in June 2015 are strikingly similar in their genetic makeup to other Ebola virus sequences from Western Africa, according to research published online today in the journal Science Advances. The study sheds light on several aspects of the "flare-ups" that have occurred in Liberia since the country was initially declared free of Ebola virus disease.

30 Apr 2016

New therapeutic target to treat bacterial infections may substitute antibiotics

Infections continue to threaten human health. With remarkable genetic flexibility, pathogenic organisms outsmart available therapies. Fortunately, microbial versatility is matched by the host immune system, which evolves in dialogue with the microbes. Therapies that enhance the beneficial effects of the immune response represent a promising, but under-explored, therapeutic alternative to antibiotics.

29 Apr 2016